XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Mergers and Acquisitions (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Business Combinations [Abstract] |
Schedule of Business Acquisitions, by Acquisition | Total estimated purchase consideration consisted of the following:
Equity consideration (1) |  | $ | 61,092,050 |
Estimated fair value of ApolloMed preferred stock held by NMM (2) |  |  | 19,118,000 |
Estimated fair value of NMM’s noncontrolling interest in APAACO (3) |  |  | 5,129,000 |
Estimated fair value of the outstanding ApolloMed stock options (4) |  |  | 1,055,333 |
Total estimated purchase consideration |  | $ | 86,394,383 |
| (1) | Equity consideration
Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock. The equity consideration, which represents a portion of the consideration deemed transferred to the pre-Merger ApolloMed stockholders in the Merger, is calculated based on the number of shares of the combined company that the pre-Merger ApolloMed stockholders would own as of the closing of the Merger.
Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders (1) |  |  | 6,109,205 |
Multiplied by the price per share of ApolloMed’s common stock (2) |  | $ | 10.00 |
Equity consideration |  | $ | 61,092,050 |
| (1) | Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.
| (2) | Represents the closing price of ApolloMed’s common stock on December 8, 2017.
| (2) | Estimated fair value of ApolloMed’s preferred shares held by NMM
NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method (“OPM”) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.
| (3) | Estimated fair value of NMM’s 50% share of APA ACO Inc.
Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM’s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM’s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior to the Merger.
| (4) | Estimated fair value of the ApolloMed outstanding stock options
The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.
Business Combination, Equity consideration |
Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders (1) |  |  | 6,109,205 |
Multiplied by the price per share of ApolloMed’s common stock (2) |  | $ | 10.00 |
Equity consideration |  | $ | 61,092,050 |
| (1) | Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.
| (2) | Represents the closing price of ApolloMed’s common stock on December 8, 2017.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | Under the acquisition method of accounting, the identifiable assets acquired and liabilities assumed of ApolloMed, the accounting acquiree, are recorded at the Merger date fair values and added to those of NMM, the accounting acquirer. The following table sets forth the preliminary allocation of the purchase consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of ApolloMed and MMG (see “MMG Transaction” below), with the excess recorded as goodwill:
Assets acquired |  |  |  |
Cash and cash equivalents |  | $ | 36,367,555 |
Accounts receivable, net |  |  | 7,261,588 |
Other receivables |  |  | 3,211,028 |
Prepaid expenses |  |  | 249,193 |
Property, plant and equipment, net |  |  | 1,114,332 |
Restricted cash |  |  | 745,220 |
Fair value of intangible assets acquired |  |  | 14,984,000 |
Deferred tax assets |  |  | 2,498,417 |
Other assets |  |  | 217,241 |
Total assets acquired |  | $ | 66,648,574 |
Liabilities assumed |  |  |  |
Accounts payable and accrued liabilities |  | $ | 8,632,893 |
Medical liabilities |  |  | 39,353,540 |
Line of credit |  |  | 25,000 |
Convertible note payable, net |  |  | 5,376,215 |
Convertible note payable - related party |  |  | 9,921,938 |
Noncontrolling interest |  |  | 3,142,000 |
Total liabilities assumed and noncontrolling interest |  | $ | 66,451,586 |
Net assets acquired |  | $ | 196,988 |
Goodwill |  | $ | 86,197,395 |
Business Acquisition, Pro Forma Information | The pro forma combined historical results, as if ApolloMed had been acquired as of January 1, 2017, are estimated as follows (unaudited):
|  | Three Months Ended September 30, 2017 |
Net revenues |  | $ | 136,196,291 |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 1,599,435 |
Weighted average common shares outstanding: |  |  |  |
Basic |  |  | 33,601,022 |
Earnings per share: |  |  |  |
basic |  | $ | 0.05 |
Weighted average common shares outstanding: |  |  |  |
diluted |  |  | 34,158,172 |
Earnings per share: |  |  |  |
diluted |  | $ | 0.05 |
|  | Nine Months Ended September 30, 2017 |
Net revenues |  | $ | 356,388,609 |
Net loss attributable to Apollo Medical Holdings, Inc. |  | $ | (507,814 | )
Weighted average common shares outstanding: |  |  |  |
Basic |  |  | 33,601,022 |
Earnings per share: |  |  |  |
basic |  | $ | (0.02 | )
Weighted average common shares outstanding: |  |  |  |
diluted |  |  | 33,601,022 |
Earnings per share: |  |  |  |
diluted |  | $ | (0.02 | )

X
- References No definition available. + Details
Name: | ameh_BusinessCombonationequityConsiderationTableTextBlock
Namespace Prefix: | ameh_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration